Literature DB >> 2574188

Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

M Clerici1, N I Stocks, R A Zajac, R N Boswell, D R Lucey, C S Via, G M Shearer.   

Abstract

We have tested the T helper cell (TH) potential of asymptomatic, HIV seropositive (HIV+) patients, using an in vitro assay for IL-2 production. Peripheral blood leukocytes (PBL) from 74 HIV+ patients and 70 HIV- control donors were tested for TH function when stimulated with influenza A virus (FLU), tetanus toxoid (TET), HLA alloantigens (ALLO), or PHA. Of the HIV+ patients, four different response patterns were observed: (a) patients who responded to all four stimuli (16%); (b) patients who were selectively unresponsive to FLU and TET, but responded to ALLO and PHA (54%); (c) patients who were unresponsive to FLU, TET, or ALLO, but responsive to PHA (16%); and (d) patients who failed to respond to any of these stimuli (14%). Our results indicate a time-dependent progression from a stage responsive to all four stimuli to a stage unresponsive to any of the stimuli tested, progressing in the order outlined above. The earliest TH defect is the loss of responses to FLU and TET, indicating a selective defect in CD4+ MHC self-restricted TH function. The later loss of ALLO and PHA IL-2 responses suggests more severe TH dysfunction involving both CD4+ and CD8+ T cells. None of these patterns of TH unresponsiveness in asymptomatic HIV+ individuals were correlated with CD4+ cell numbers nor with Walter Reed staging criteria. This study indicates that the in vitro TH assay used can detect multiple stages of immune dysregulation early in the course of HIV infection and raises the possibility that staging of HIV+ patients should include in vitro TH functional analyses of the type described here.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574188      PMCID: PMC304069          DOI: 10.1172/JCI114376

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

2.  Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.

Authors:  T Folks; J Kelly; S Benn; A Kinter; J Justement; J Gold; R Redfield; K W Sell; A S Fauci
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

3.  The Walter Reed staging classification for HTLV-III/LAV infection.

Authors:  R R Redfield; D C Wright; E C Tramont
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

4.  Four-year prospective study of homosexual men: correlation of immunologic abnormalities, clinical status, and serology to human immunodeficiency virus.

Authors:  W el-Sadr; M Marmor; S Zolla-Pazner; R E Stahl; R Lyden; D William; S D'Onofrio; S H Weiss; W C Saxinger
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

5.  Follow-up at 41/2 years on homosexual men with generalized lymphadenopathy.

Authors:  U Mathur-Wagh; D Mildvan; R T Senie
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

6.  Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study.

Authors:  M Melbye; R J Biggar; P Ebbesen; C Neuland; J J Goedert; V Faber; I Lorenzen; P Skinhøj; R C Gallo; W A Blattner
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

7.  Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members.

Authors:  J J Goedert; R J Biggar; S H Weiss; M E Eyster; M Melbye; S Wilson; H M Ginzburg; R J Grossman; R A DiGioia; W C Sanchez
Journal:  Science       Date:  1986-02-28       Impact factor: 47.728

8.  The time from infection with human immunodeficiency virus (HIV) to the onset of AIDS.

Authors:  J M Taylor; K Schwartz; R Detels
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

9.  A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).

Authors:  G M Shearer; D C Bernstein; K S Tung; C S Via; R Redfield; S Z Salahuddin; R C Gallo
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

10.  Graft-vs-host reaction limited to a class II MHC difference results in a selective deficiency in L3T4+ but not in Lyt-2+ T helper cell function.

Authors:  M Moser; T Mizuochi; S O Sharrow; A Singer; G M Shearer
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

View more
  150 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.

Authors:  R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

3.  CD28 costimulation and CD28 expression in T lymphocyte subsets in HIV-1 infection with and without progression to AIDS.

Authors:  H Choremi-Papadopoulou; N Panagiotou; E Samouilidou; F Kontopidou; V Viglis; A Antoniadou; J Kosmidis; T Kordossis
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 4.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

5.  Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.

Authors:  Elizabeth Connick; Ronald J Bosch; Evgenia Aga; Rick Schlichtemeier; Lisa M Demeter; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2011-09-01       Impact factor: 3.731

6.  When should asymptomatic patients with HIV infection be treated with zidovudine?

Authors:  B G Gazzard
Journal:  BMJ       Date:  1992-02-22

7.  HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy.

Authors:  S Resino; I Galán; A Pérez; J A León; E Seoane; D Gurbindo; M Angeles Muñoz-Fernandez
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

8.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  Retinoic acid inhibition of ex vivo human immunodeficiency virus-associated apoptosis of peripheral blood cells.

Authors:  Y Yang; J Bailey; M S Vacchio; R Yarchoan; J D Ashwell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Quantitative analysis of CD4+ T cell function in the course of human immunodeficiency virus infection. Gradual decline of both naive and memory alloreactive T cells.

Authors:  L Meyaard; S A Otto; B Hooibrink; F Miedema
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.